Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

[1]  S. Tapscott,et al.  DUX4 Suppresses MHC Class I to Promote Cancer Immune Evasion and Resistance to Checkpoint Blockade. , 2019, Developmental cell.

[2]  X. Mu,et al.  Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). , 2019, Journal of Clinical Oncology.

[3]  T. Powles,et al.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[4]  R. Motzer,et al.  Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[5]  J. Reeves,et al.  Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma , 2018, Nature Medicine.

[6]  Jennifer G. Lyons,et al.  Characteristics, treatment patterns and safety events from 4 cohorts of advanced or metastatic cancer patients based on health care claims data. , 2018 .

[7]  J. Larkin,et al.  Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. , 2018, The Lancet. Oncology.

[8]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[9]  Michael C. Heinold,et al.  The landscape of genomic alterations across childhood cancers , 2018, Nature.

[10]  T. Chan,et al.  Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab , 2017, Cell.

[11]  J. Lunceford,et al.  IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade , 2017, The Journal of clinical investigation.

[12]  E. Amir,et al.  HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer , 2017, British Journal of Cancer.

[13]  J. Schlom,et al.  Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. , 2017, The Lancet. Oncology.

[14]  N. Neamati,et al.  Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases , 2017, Theranostics.

[15]  J. Sosman,et al.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2017, Cell.

[16]  Stuart J. Andrews,et al.  Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations , 2016, Genome Medicine.

[17]  H. Decker,et al.  Immunological properties of oxygen-transport proteins: hemoglobin, hemocyanin and hemerythrin , 2016, Cellular and Molecular Life Sciences.

[18]  A. Kennedy,et al.  Role of lipids in the metabolism and activation of immune cells. , 2016, The Journal of nutritional biochemistry.

[19]  P. Ross-Macdonald,et al.  Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma , 2016, Clinical Cancer Research.

[20]  Keunchil Park,et al.  Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial , 2016, The Lancet.

[21]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[22]  P. Hegde,et al.  Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC) , 2015, Journal of Immunotherapy for Cancer.

[23]  Erik Sahai,et al.  Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity , 2015, Cell.

[24]  A. Ribas.  Adaptive Immune Resistance: How Cancer Protects from Immune Attack. , 2015, Cancer discovery.

[25]  S. Signoretti,et al.  Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial , 2014, Clinical Cancer Research.

[26]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[27]  A. McKenna,et al.  The genomic landscape of pediatric Ewing sarcoma. , 2014, Cancer discovery.

[28]  Benjamin Schubert,et al.  OptiType: precision HLA typing from next-generation sequencing data , 2014, Bioinform..

[29]  Demin Li,et al.  A Core Human Primary Tumor Angiogenesis Signature Identifies the Endothelial Orphan Receptor ELTD1 as a Key Regulator of Angiogenesis , 2013, Cancer cell.

[30]  The Cancer Genome Atlas Research Network.  COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.

[31]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[32]  Yi-Wen Chen,et al.  DUX4 Differentially Regulates Transcriptomes of Human Rhabdomyosarcoma and Mouse C2C12 Cells , 2013, PloS one.

[33]  Matthew J. Brauer,et al.  Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies , 2013, Clinical Cancer Research.

[34]  Elaine R. Mardis,et al.  Novel mutations target distinct subgroups of medulloblastoma , 2012, Nature.

[35]  Abraham P. Fong,et al.  DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy. , 2012, Developmental cell.

[36]  J. Mesirov,et al.  Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..

[37]  J. Scheller,et al.  The pro- and anti-inflammatory properties of the cytokine interleukin-6. , 2011, Biochimica et biophysica acta.

[38]  Kenneth G. C. Smith,et al.  FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications , 2010, Nature Reviews Immunology.

[39]  J. Zimmer,et al.  Cytokine Levels Correlate with Immune Cell Infiltration after Anti-VEGF Therapy in Preclinical Mouse Models of Breast Cancer , 2009, PloS one.

[40]  S. Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[41]  H. Zou,et al.  Regularization and variable selection via the elastic net , 2005 .

[42]  R. Gray.  Modeling Survival Data: Extending the Cox Model , 2002 .

[43]  H Nagura,et al.  Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. , 2001, Cancer research.

[44]  P. Grambsch,et al.  Modeling Survival Data: Extending the Cox Model , 2000 .

[45]  R. Gill,et al.  Cox's regression model for counting processes: a large sample study : (preprint) , 1982 .

[46]  Ash A. Alizadeh,et al.  SUPPLEMENTARY NOTE , 1879, Botanical Gazette.

[47]  Kenneth G. C. Smith,et al.  FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications , 2010, Nature Reviews Immunology.